NCT06020833View on ClinicalTrials.gov

A Single-arm Trial of Roxadustat Combined With Retinoic Acid in the Treatment of Refractory Low-risk MDS

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 31, 2023

Primary Completion Date

October 31, 2025

Study Completion Date

December 31, 2026

Conditions

Myelodysplastic Syndromes

Interventions

DRUG

Roxadustat in combination with retinoic acid

Roxadustat 150mg po qod combined with retinoic acid 20mg po bid

All Listed Sponsors

lead

Peking Union Medical College Hospital

OTHER

NCT06020833 - A Single-arm Trial of Roxadustat Combined With Retinoic Acid in the Treatment of Refractory Low-risk MDS | Biotech Hunter | Biotech Hunter